(Total Views: 353)
Posted On: 07/02/2025 1:01:50 PM
Post# of 154881
Max reply to Ken on LinkedIn:
“Ken Chowder Very good question Ken! As you pointed out, CRC is known to be a cold tumor, not much PD-L1 expression. We hope to see a similar impact on PD-L1 upregulation prospectively with Leronlimab, allowing patients potentially to benefit from ICIs. That option has been added in the CRC study. Best!”
“Ken Chowder Very good question Ken! As you pointed out, CRC is known to be a cold tumor, not much PD-L1 expression. We hope to see a similar impact on PD-L1 upregulation prospectively with Leronlimab, allowing patients potentially to benefit from ICIs. That option has been added in the CRC study. Best!”
(7)
(0)
